Shemesh Shay
Known title: Chief Development OfficerCIK: 0001896056
Shemesh Shay's purchase track record
How the stock did after each of Shemesh Shay's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
9
of 9 since February 4, 2022
Stock higher 6 months later
78%
3 months: 56%
Median 6-month return
+49.4%
3 months: +5.9%
Beat the S&P 500
78%
median +42.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/10/2024 | NVCT | $7K | +5.9% | +68.9% | +14.8% |
| 3/15/2023 | NVCT | $12K | +66.1% | +26.9% | +14.8% |
| 12/21/2022 | NVCT | $4K | +66.9% | +141.4% | +12.6% |
| 11/16/2022 | NVCT | $2K | +45.8% | +139.4% | +5.1% |
| 9/23/2022 | NVCT | $2K | -1.6% | +49.4% | +7.5% |
| 8/31/2022 | NVCT | $28K | -9.3% | +42.2% | -0.1% |
| 5/20/2022 | NVCT | $5K | -42.0% | -53.4% | +1.6% |
| 5/12/2022 | NVCT | $25K | -52.2% | -60.5% | +0.7% |
| 2/4/2022 | NVCT | $10K | +460.0% | +161.8% | -7.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NVCT | ▲ Buy | Grant | 150,000 | $0 | 1/6/2026 | View on chart |
| NVCT | ▲ Buy | Grant | 150,000 | $0 | 1/2/2025 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,113 | $7K | 5/10/2024 | View on chart |
| NVCT | ▲ Buy | Grant | 130,000 | $0 | 1/3/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 420 | $5K | 3/21/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 670 | $7K | 3/15/2023 | View on chart |
| NVCT | ▲ Buy | Grant | 115,000 | $0 | 1/12/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $4K | 12/21/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 150 | $1K | 11/17/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 150 | $1K | 11/16/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 220 | $2K | 9/23/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 404 | $3K | 9/2/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,530 | $12K | 9/1/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,476 | $12K | 8/31/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 300 | $5K | 5/20/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 142 | $3K | 5/17/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 100 | $2K | 5/16/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 36 | $525 | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 1,184 | $19K | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 58 | $963 | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Grant | 60,000 | $0 | 4/1/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 846 | $3K | 2/7/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 2,100 | $7K | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Nuvectis Pharma to speak at Maxim Growth Summit 2026
Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.
Nuvectis Pharma to speak at Maxim Growth Summit 2026. Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.